Regenxbio
RGNX
78 hedge funds and large institutions have $339M invested in Regenxbio in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
69.11% more ownership
Funds ownership: 0% → 69.11% (+69%)
44% more capital invested
Capital invested by funds: $236M → $339M (+$103M)
24% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 25
10% more funds holding
Funds holding: 71 → 78 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.2M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.89M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$4.66M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.04M |
| 5 |
NCM
Numina Capital Management
New York
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$9.32M |
| 2 |
VMI
VHCP Management II
New York
|
-$4.66M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.1M |
| 4 |
Axa
Paris,
France
|
-$4.04M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.29M |
RGNX Hedge Fund Activity: Q4 2016 in Review
78 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2016, worth a combined $339M — up 44% from $236M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RGNX positions and 10 closed out — a net gain of 8 holders — while 31 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27.2M. The largest seller was Vivo Capital, cutting an estimated $9.32M.
- 78 institutional investors held Regenxbio (RGNX) as of Q4 2016, up from 71 in Q3 2016.
- Funds reported $339M of Regenxbio stock for Q4 2016, up 44% quarter-over-quarter.
- 18 funds opened new Regenxbio positions in Q4 2016 and 10 closed out, a net change of +8 holders.
- The largest Regenxbio buyer in Q4 2016 was Fidelity Investments, an estimated $27.2M added.
- The largest Regenxbio seller in Q4 2016 was Vivo Capital, an estimated $9.32M sold.
Based on aggregated 13F filings for Q4 2016.